Arbutus Biopharma Corp (ABUS) concluded trading on Wednesday at a closing price of $4.20, with 3.35 million shares of worth about $14.08 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 51.08% during that period and on October 16, 2024 the price saw a gain of about 2.19%. Currently the company’s common shares owned by public are about 169.87M shares, out of which, 146.67M shares are available for trading.
Stock saw a price change of 11.70% in past 5 days and over the past one month there was a price change of 2.94%. Year-to-date (YTD), ABUS shares are showing a performance of 68.00% which increased to 122.22% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.69 but also hit the highest price of $4.72 during that period. The average intraday trading volume for Arbutus Biopharma Corp shares is 1.10 million. The stock is currently trading 7.29% above its 20-day simple moving average (SMA20), while that difference is up 6.03% for SMA50 and it goes to 31.46% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Arbutus Biopharma Corp (NASDAQ: ABUS) currently have 169.87M outstanding shares and institutions hold larger chunk of about 51.24% of that.
The stock has a current market capitalization of $792.88M and its 3Y-monthly beta is at 1.91. It has posted earnings per share of -$0.44 in the same period. It has Quick Ratio of 6.56 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABUS, volatility over the week remained 4.00% while standing at 3.53% over the month.
Stock’s fiscal year EPS is expected to rise by 12.27% while it is estimated to increase by 9.33% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on February 02, 2022 offering a Buy rating for the stock and assigned a target price of $5 to it. Coverage by Jefferies stated Arbutus Biopharma Corp (ABUS) stock as a Hold in their note to investors on February 25, 2021, suggesting a price target of $5 for the stock. On December 17, 2020, H.C. Wainwright Initiated their recommendations, while on July 27, 2020, JMP Securities Resumed their ratings for the stock with a price target of $8. Stock get a Neutral rating from Robert W. Baird on July 24, 2020.
